| 赵 婷,牛星鉴,张清媛.PARP抑制剂在乳腺癌治疗中的研究进展[J].肿瘤学杂志,2023,29(3):191-197. |
| PARP抑制剂在乳腺癌治疗中的研究进展 |
| Research Progress on PARP Inhibitors in Breast Cancer Treatment |
| 投稿时间：2022-11-30 |
| DOI：10.11735/j.issn.1671-170X.2023.03.B004 |
|
 |
| 中文关键词: PARP抑制剂 乳腺癌 乳腺癌易感基因 DNA损伤修复 |
| 英文关键词:poly ADP-ribose polymerase inhibitor breast cancer breast cancer susceptibility gene repair of DNA damage |
| 基金项目: |
|
| 摘要点击次数: 468 |
| 全文下载次数: 337 |
| 中文摘要: |
| 摘 要：PARP抑制剂作为一种新型的小分子靶向药物，已经在乳腺癌中进行了广泛的研究，其单药在早期及晚期乳腺癌患者中已经显示出了可观的疗效，但长期单药应用所产生的PARP耐药无法避免。研究表明，PARP抑制剂与其他信号通路靶向药物，如免疫检查点抑制剂、PI3K/AKT通路抑制剂等药物的联合应用可能增强其肿瘤杀伤作用。全文就PARP抑制剂在早期及晚期乳腺癌中的单药及联合应用的研究进展进行综述。 |
| 英文摘要: |
| Abstract： As a new type of small molecule targeted drug， poly ADP-ribose polymerase(PARP) inhibitor has been widely studied in breast cancer. Its single drug has shown considerable efficacy in early and advanced breast cancer patients， but the drug resistance caused by long-term single drug application can not be avoided. Studies have shown that the combination of PARP inhibitors with other signaling pathway targeted drugs， such as immune checkpoint inhibitors and PI3K/AKT pathway inhibitors， may enhance their tumor killing effect. This article reviews the research progress of PARP inhibitors in treatment of early and advanced breast cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |